Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome
Open Access
- 15 August 2002
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 16 (8) , 1407-1430
- https://doi.org/10.1046/j.1365-2036.2002.01305.x
Abstract
This consensus document reviews the current status of the epidemiology, social impact, patient quality of life, pathophysiology, diagnosis and treatment of irritable bowel syndrome. Current evidence suggests that two major mechanisms may interact in irritable bowel syndrome: altered gastrointestinal motility and increased sensitivity of the intestine. However, other factors, such as psychosocial factors, intake of food and prior infection, may contribute to its development. Management of patients is based on a positive diagnosis of the symptom complex, careful history and physical examination to exclude ‘red flags’ as risk factors for organic disease, and, if indicated, investigations to exclude other disorders. Therapeutic choices include dietary fibre for constipation, opioid agents for diarrhoea and low‐dose antidepressants or infrequent use of antispasmodics for pain, although the evidence basis for efficacy is limited or in some cases absent. Psychotherapy and hypnotherapy are the subject of ongoing study. Treatment should be tailored to patient needs and fears. Novel therapies are emerging, and drugs acting on serotonin receptors have proven efficacy and a scientific rationale and, if approved, should be useful in the overall management of patients with irritable bowel syndrome. Patient and physician education, early identification of psychosocial issues and better therapies are important strategies to reduce the suffering and societal cost of irritable bowel syndrome.Keywords
This publication has 182 references indexed in Scilit:
- First Pharmacokinetic—Pharmacodynamic Study in Humans with a Selective 5‐Hydroxytryptamine4 Receptor AgonistThe Journal of Clinical Pharmacology, 1997
- Gender variations in clinical pain experiencePain, 1996
- Antidepressants for functional gastrointestinal syndromesDigestive Diseases and Sciences, 1994
- U. S. Householder survey of functional gastrointestinal disordersDigestive Diseases and Sciences, 1993
- Terminal ileal mucosal mast cells in irritable bowel syndromeDigestive Diseases and Sciences, 1993
- Effects of desipramine on irritable bowel syndrome compared with atropine and placeboDigestive Diseases and Sciences, 1987
- Increased colonic motility during exposure to a stressful situationDigestive Diseases and Sciences, 1985
- Role of loperamide and placebo in management of irritable bowel syndrome (IBS)Digestive Diseases and Sciences, 1984
- Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgencyDigestive Diseases and Sciences, 1982
- Irritable colon and depressionPsychosomatics, 1978